Stifel Nicolaus Issues Positive Forecast for HLS Therapeutics (TSE:HLS) Stock Price

HLS Therapeutics (TSE:HLS) had its price target increased by equities research analysts at Stifel Nicolaus from C$3.50 to C$4.00 in a research report issued on Wednesday,BayStreet.CA reports. The brokerage presently has a “hold” rating on the stock. Stifel Nicolaus’ target price suggests a potential downside of 9.30% from the stock’s current price.

HLS Therapeutics Stock Performance

HLS traded up C$0.10 on Wednesday, reaching C$4.41. 8,411 shares of the stock were exchanged, compared to its average volume of 15,044. The company’s 50-day moving average price is C$4.16 and its 200 day moving average price is C$3.79. The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01. The firm has a market capitalization of C$98.11 million, a PE ratio of -4.42 and a beta of 1.07. HLS Therapeutics has a fifty-two week low of C$3.00 and a fifty-two week high of C$5.48.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.